In neuroblastoma, Mdm2 can acts as a tumor promoting factor as seen in Mdm2 haploinsufficient (Mdm2+/-) MYCN transgenic mice which show a decreased tumor incidence, latency, and reduced tumor growth (74). The gene discussed is MYCN; the disease is neuroblastoma.